Literature DB >> 222811

Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivo.

D W Bilheimer, N J Stone, S M Grundy.   

Abstract

To investigate the gene-dosage effect in familial hypercholesterolemia (FH), metabolic studies were conducted in a group of well-characterized patients with either heterozygous (n = 7) or homozygous (n = 7) FH and the results were compared to those obtained in normal subjects (n = 6). The turnover of (125)I-labeled low-density lipoprotein (LDL) was measured in all of the normals, all but one of the FH heterozygotes, and in all of the homozygotes. Chemical cholesterol balance was performed simultaneously with the (125)I-LDL turnover in all seven of the homozygotes. With regard to (125)I-LDL turnover, FH homozygotes, who possess two doses of the mutant FH gene, exhibited a threefold increase in the rate of apoLDL synthesis while the fractional catabolic rate (FCR) for the apoprotein was only about one-third of normal. Heterozygotes, who have only one dose of the mutant FH gene, exhibited intermediate values for both parameters; that is, the FCR was two-thirds of normal and the apoLDL synthetic rate was 1.7-fold greater than normal. THE DATA INDICATE THAT THE SINGLE GENE DEFECT IN FH PRODUCES TWO DISTINCT ABNORMALITIES OF LDL METABOLISM: (a) an increase in the synthetic rate for apoLDL and (b) a decrease in the efficiency of apoLDL catabolism. Both defects are more severe in FH homozygotes than in heterozygotes. The FCR for apoLDL in the homozygotes appeared to be fixed at congruent with 17%/d whereas the plasma LDL level varied about twofold. These findings suggest that the twofold variation in plasma LDL levels observed in these seven patients is caused by variation in the plasma apoLDL synthetic rates. Consistent with this conclusion was the finding that the correlation between the plasma LDL level and the apoLDL synthetic rates in the seven FH homozygotes was 0.943. The rate of total body cholesterol synthesis determined by chemical cholesterol balance did not appear to clearly differ between normals and patients with either one or two mutant FH genes. Two of the youngest FH homozygotes exhibited cholesterol overproduction but the other five did not. No consistent abnormality of bile acid metabolism was observed in these patients. Because the daily plasma flux of cholesterol on LDL is about threefold greater than the amount of cholesterol produced per day, a significant amount of the cholesterol liberated from LDL degradation must be reused.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 222811      PMCID: PMC372147          DOI: 10.1172/JCI109490

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Distribution and degradation of human serum albumin labeled with I 131 by different techniques.

Authors:  J L STEINFELD; R R PATON; A L FLICK; R A MILCH; F E BEACH; D L TABERN
Journal:  Ann N Y Acad Sci       Date:  1957-08-30       Impact factor: 5.691

Review 2.  The low-density lipoprotein pathway and its relation to atherosclerosis.

Authors:  J L Goldstein; M S Brown
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

3.  Non-stedy-state studies of low-density-liproprotein turnover in familial hypercholesterolaemia.

Authors:  G R Thompson; T Spinks; A Ranicar; N B Myant
Journal:  Clin Sci Mol Med       Date:  1977-04

4.  Genetics of the low density lipoprotein receptor. Diminished receptor activity in lymphocytes from heterozygotes with familial hypercholesterolemia.

Authors:  D W Bilheimer; Y K Ho; M S Brown; R G Anderson; J L Goldstein
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

5.  Needed: new therapy for hypercholesterolemia.

Authors:  D W Bilheimer
Journal:  N Engl J Med       Date:  1977-03-03       Impact factor: 91.245

6.  Simultaneous measurement of apolipoprotein B turnover in very-low-and low-density lipoproteins in familial hypercholesterolaemia.

Authors:  A K Soutar; N B Myant; G R Thompson
Journal:  Atherosclerosis       Date:  1977-11       Impact factor: 5.162

7.  New insights into cholesterol dynamics.

Authors:  T A Miettinen
Journal:  Arch Surg       Date:  1978-01

8.  Genetics of the LDL receptor: evidence that the mutations affecting binding and internalization are allelic.

Authors:  J L Goldstein; M S Brown; N J Stone
Journal:  Cell       Date:  1977-11       Impact factor: 41.582

9.  Regulation of low density lipoprotein receptor activity in freshly isolated human lymphocytes.

Authors:  Y K Ho; S Brown; D W Bilheimer; J L Goldstein
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

10.  Regulation of cholesterol synthesis by low density lipoprotein in isolated human lymphocytes. Comparison of cells from normal subjects and patients with homozygous familial hypercholesterolemia and abetalipoproteinemia.

Authors:  Y K Ho; J R Faust; D W Bilheimer; M S Brown; J L Goldstein
Journal:  J Exp Med       Date:  1977-06-01       Impact factor: 14.307

View more
  35 in total

1.  Probing of the expression of the low-density lipoprotein receptor in vivo using an anti-receptor monoclonal antibody.

Authors:  E Gherardi; D E Bowyer; C Fitzsimmons; T Le Cras; A Hutchings; G Butcher
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

2.  Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits.

Authors:  T Kita; M S Brown; D W Bilheimer; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

3.  Treatment of familial hypercholesterolemia by portacaval anastomosis: effect on cholesterol metabolism and pool sizes.

Authors:  D J McNamara; E H Ahrens; R Kolb; C D Brown; T S Parker; N O Davidson; P Samuel; R M McVie
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

4.  Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.

Authors:  D W Bilheimer; S M Grundy; M S Brown; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

5.  Low density lipoprotein degradation by mononuclear cells from normal and dyslipoproteinemic subjects.

Authors:  A M Lees; R S Lees
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

Review 6.  Novel Therapies for Familial Hypercholesterolemia.

Authors:  Justin Parizo; Ashish Sarraju; Joshua W Knowles
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-11

Review 7.  Pathophysiology of human lipoprotein receptors: clinical consequences of a cellular defect.

Authors:  J Shepherd; C J Packard
Journal:  J Clin Pathol       Date:  1984-01       Impact factor: 3.411

8.  Technetium-99m labelled LDL as a tracer for quantitative LDL scintigraphy. I. Tracer purification, in vitro and in vivo long-term stability, in vitro validation and biodistribution.

Authors:  T Leitha; M Hermann; M Hüttinger; P Angelberger; R Dudczak
Journal:  Eur J Nucl Med       Date:  1993-08

9.  Technetium-99m labelled LDL as a tracer for quantitative LDL scintigraphy. II. In vivo validation, LDL receptor-dependent and unspecific hepatic uptake and scintigraphic results.

Authors:  T Leitha; A Staudenherz; B Gmeiner; M Hermann; M Hüttinger; R Dudczak
Journal:  Eur J Nucl Med       Date:  1993-08

10.  Regulation of plasma LDL: the apoB paradigm.

Authors:  Allan D Sniderman; Jacqueline De Graaf; Patrick Couture; Ken Williams; Robert S Kiss; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.